Revising the ABIDE MCI to dementia prediction model for automated cerebrospinal fluid assays.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
van der Veere Pieter J, van Harten Argonde C, van Maurik Ingrid S, Teunissen Charlotte E, Barkhof Frederik, Vos Stephanie J B, Froelich Lutz, Kornhuber Johannes, Wiltfang Jens, Maier Wolfgang, Peters Oliver, Rüther Eckart, Frisoni Giovanni B, Spiru Luiza, Freund-Levi Yvonne, Wallin Åsa K, Hampel Harald, Tsolaki Magda, Kłoszewska Iwona, Mecocci Patrizia, Vellas Bruno, Lovestone Simon, Galluzzi Samantha, Herukka Sanna-Kaisa, Santana Isabel, Baldeiras I, de Mendonca Alexandre, Silva Dina, Chetelat Gael, Poisnel Géraldine, Visser Pieter Jelle, Johnson Sterling C, Stormrud Erik, Hansson Oskar, Palmqvist Sebastian, Piñol-Ripoll Gerard, Alzheimer's Disease Neuroimaging Initiative, Berkhof Johannes, van der Flier Wiesje M
Аннотация
METHODS: We included 2413 MCI participants (998 [41%] amyloid-positive) from seven observational cohorts. Elecsys was used in 958 (40%) participants. The parameters of the previous ABIDE Cox model were re-estimated. Model discrimination and calibration were evaluated with leave-one-cohort-out cross-validation.
RESULTS: During follow-up, 1034 (42%; 585 [58%] amyloid-positive) participants developed dementia. Discrimination was good with Harrell's C of 0.70 (95% confidence interval [CI]: 0.66-0.73). Calibration was good in the total population and amyloid-positive subgroup, with substantial predicted progression risks for all amyloid-positive participants.
DISCUSSION: We refitted the ABIDE model, predicting MCI to dementia progression, with automated CSF measurements. The model was well calibrated in amyloid-positive patients and may support clinical discussions regarding ATTs.